With 3.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.25 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $3.0050 whereas the lowest price it dropped to was $2.8101. The 52-week range on CGC shows that it touched its highest point at $23.10 and its lowest point at $2.98 during that stretch. It currently has a 1-year price target of $4.02. Beta for the stock currently stands at 1.20.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CGC was down-trending over the past week, with a drop of -18.13%, but this was down by -37.72% over a month. Three-month performance dropped to -53.24% while six-month performance fell -47.45%. The stock lost -87.32% in the past year, while it has lost -43.44% so far this year. A look at the trailing 12-month EPS for CGC yields -16.06 with Next year EPS estimates of -0.81. For the next quarter, that number is -0.33. This implies an EPS growth rate of 90.94% for this year and 83.41% for next year. EPS is expected to grow by 13.28% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -76.81%.
Float and Shares Shorts:
At present, 91.11 million CGC shares are outstanding with a float of 73.89 million shares on hand for trading. On Feb 15, 2024, short shares totaled 4.73 million, which was 5.19% higher than short shares on Jan 12, 2024. In addition to Mr. David Eric Klein as the firm’s CEO & Director, Ms. Judy Eunjoo Hong serves as its CFO & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 4.91% of CGC’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CGC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, CGC has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CGC currently yields $0.00. In the past year, CGC’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CGC has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.
Summary of Insider Activity:
Insiders traded CGC stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 20 while that of sell transactions has risen to 19 over the past year. The total number of shares bought during that period was 106,108,910 while 100,291,170 shares were sold.
